FCT Combustion
Ahmed Zoheir, MBA, currently serves as Group Chief Financial Officer at FCT Combustion since March 2022. Prior to this role, Ahmed held positions as Manager Private Client at Venture Private Advisory and Chief Financial Officer at several companies, including Mayo Foods PTY LTD and Emirates National Investment. With extensive experience in financial management, Ahmed has expertise in creating budgets, conducting financial due diligence, and managing financial reporting processes. Ahmed's career spans over two decades, with roles ranging from Finance Manager at PHARMA WORLD LTD to Retail Accounting Finance at Vodafone. Ahmed holds an MBA in Business Administration from Paris ESLSCA Business School and a Bachelor's Degree in Accounting and Finance from Ain Shams University.
This person is not in any teams
FCT Combustion
FCT Combustion is a world leader in high temperature processing plants for heavy industry. With a focus on delivering environmentally friendly technologies, FCT specializes in helping clients achieve significant emissions reductions, increased fuel efficiency, higher levels of productivity, and the flexibility to meet ever-changing requirements. Whether you need a complete plant or individual equipment, FCT is the trusted partner to meet your pyro-processing requirements, and offers: 🔥 Complete plants and solutions such as clay calcining plants, drying plants for clay and other materials, mobile and semi-mobile plants, heat treatment plants, curing plants, and hot gas generation systems. 🔥 Leading combustion products including burner systems, hot gas generators, flash calciners, rotary kiln calciners, fuel handling systems, and burner management systems. 🔥 Specialist services for pyro-processing, such as fuel conversions, in-house Computational Fluid Dynamics (CFD) services, burner upgrades, commissioning, site services, process auditing, and consulting. Our network of international offices provide local, personalized support to deliver the best solutions for your process and environment. Our offices are located in Australia, Austria, Brazil, China, Germany and the USA, and our in-house R&D facility is located in South Australia.